Clinical Pharmacokinetics and Administration of Established Platinum Drugs

Overview

Journal Drugs

Specialty Pharmacology

Date 2000 Jun 23

PMID 10864227

Citations 39

Authors

P J ODwyer

J P Stevenson

S W Johnson

Affiliations

Soon will be listed here.

Abstract

We review the pharmacology and clinical administration of the commonly used platinum-based anticancer drugs cisplatin and carboplatin, and the more recently approved diamminocyclohexane-based oxaliplatin. The development of analogues of cisplatin has been focused upon identifying compounds with less toxicity and with a different spectrum of activity. Carboplatin exemplifies the former, while the initial data with oxaliplatin support its activity in cisplatin-resistant tumours. The clinical pharmacokinetics of the drugs are reviewed. Incorporation of these data into the design of clinical regimens has permitted individualised therapy with carboplatin, and has enhanced safety. Additional investigation of the pharmacodynamics of all of these agents is expected to result in their selective application. The clinical effects of these analogues are discussed.

Citing Articles

Understanding Cisplatin Pharmacokinetics and Toxicodynamics to Predict and Prevent Kidney Injury.

Thompson L, Joy M J Pharmacol Exp Ther. 2024; 391(3):399-414.

PMID: 39322416 PMC: 11585315. DOI: 10.1124/jpet.124.002287.

Unveiling FDA-approved Drugs and Formulations in the Management of Bladder Cancer: A Review.

Bansal K, Chaudhary N, Bhati H, Singh V Curr Pharm Biotechnol. 2024; 26(1):48-62.

PMID: 38797905 DOI: 10.2174/0113892010314650240514053735.

Early and Long-Term Ototoxicity Noted in Children Due to Platinum Compounds: Prevalence and Risk Factors.

Romano A, Rivetti S, Brigato F, Mastrangelo S, Attina G, Maurizi P Biomedicines. 2023; 11(2).

PMID: 36830798 PMC: 9953080. DOI: 10.3390/biomedicines11020261.

Pharmacokinetics of Carboplatin in Combination with Low-Dose Cyclophosphamide in Female Dogs with Mammary Carcinoma.

Machado M, Yamamoto P, Pippa L, De Moraes N, Neves F, Portela R Animals (Basel). 2022; 12(22).

PMID: 36428336 PMC: 9686876. DOI: 10.3390/ani12223109.

Evaluation of anticancer effects of carboplatin-gelatin nanoparticles in different sizes synthesized with newly self-assembly method by exposure to IR light.

Danisman-Kalindemirtas F, Kariper I, Erdemir G, Sert E, Erdem-Kuruca S Sci Rep. 2022; 12(1):10686.

PMID: 35739313 PMC: 9226150. DOI: 10.1038/s41598-022-15051-7.

References

Burchenal J, Irani G, Kern K, Lokys L, TURKEVICH J . 1,2-Diaminocyclohexane platinum derivatives of potential clinical value. Recent Results Cancer Res. 1980; 74:146-55. DOI: 10.1007/978-3-642-81488-4_19. View

Evans B, Raju K, Calvert A, Harland S, Wiltshaw E . Phase II study of JM8, a new platinum analog, in advanced ovarian carcinoma. Cancer Treat Rep. 1983; 67(11):997-1000. View

Cvitkovic E, Spaulding J, Bethune V, Martin J, Whitmore W . Improvement of cis-dichlorodiammineplatinum (NSC 119875): therapeutic index in an animal model. Cancer. 1977; 39(4):1357-61. DOI: 10.1002/1097-0142(197704)39:4<1357::aid-cncr2820390402>3.0.co;2-c. View

Raymond E, Chaney S, Taamma A, Cvitkovic E . Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol. 1998; 9(10):1053-71. DOI: 10.1023/a:1008213732429. View

MATHE G, KIDANI Y, Segiguchi M, Eriguchi M, Fredj G, Peytavin G . Oxalato-platinum or 1-OHP, a third-generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cis-platinum and carboplatinum. Biomed Pharmacother. 1989; 43(4):237-50. DOI: 10.1016/0753-3322(89)90003-6. View

Connors T, Jones M, Ross W, Braddock P, Khokhar A, Tobe M . New platinum complexes with anti-tumour activity. Chem Biol Interact. 1972; 5(6):415-24. DOI: 10.1016/0009-2797(72)90078-6. View

Gralla R, Osoba D, Kris M, Kirkbride P, Hesketh P, Chinnery L . Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology. J Clin Oncol. 1999; 17(9):2971-94. DOI: 10.1200/JCO.1999.17.9.2971. View

Vermorken J, van der Vijgh W, Klein I, Hart A, Gall H, Pinedo H . Pharmacokinetics of free and total platinum species after short-term infusion of cisplatin. Cancer Treat Rep. 1984; 68(3):505-13. View

van der Vijgh W . Clinical pharmacokinetics of carboplatin. Clin Pharmacokinet. 1991; 21(4):242-61. DOI: 10.2165/00003088-199121040-00002. View

10.

Belt R, Himmelstein K, Patton T, Bannister S, Sternson L, Repta A . Pharmacokinetics of non-protein-bound platinum species following administration of cis-dichlorodiammineplatinum(II). Cancer Treat Rep. 1979; 63(9-10):1515-21. View

11.

Hayes D, Cvitkovic E, GOLBEY R, Scheiner E, Helson L, KRAKOFF I . High dose cis-platinum diammine dichloride: amelioration of renal toxicity by mannitol diuresis. Cancer. 1977; 39(4):1372-81. DOI: 10.1002/1097-0142(197704)39:4<1372::aid-cncr2820390404>3.0.co;2-j. View

12.

Ozols R, Ostchega Y, Myers C, Young R . High-dose cisplatin in hypertonic saline in refractory ovarian cancer. J Clin Oncol. 1985; 3(9):1246-50. DOI: 10.1200/JCO.1985.3.9.1246. View

13.

Reed E, Ozols R, Tarone R, Yuspa S, Poirier M . Platinum-DNA adducts in leukocyte DNA correlate with disease response in ovarian cancer patients receiving platinum-based chemotherapy. Proc Natl Acad Sci U S A. 1987; 84(14):5024-8. PMC: 305239. DOI: 10.1073/pnas.84.14.5024. View

14.

Alberts D, Liu P, Hannigan E, OToole R, Williams S, Young J . Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med. 1996; 335(26):1950-5. DOI: 10.1056/NEJM199612263352603. View

15.

Loehrer P, Einhorn L . Drugs five years later. Cisplatin. Ann Intern Med. 1984; 100(5):704-13. DOI: 10.7326/0003-4819-100-5-704. View

16.

Judson I, Kelland L . New developments and approaches in the platinum arena. Drugs. 2000; 59 Suppl 4:29-36; discussion 37-8. DOI: 10.2165/00003495-200059004-00004. View

17.

Harland S, Newell D, Siddik Z, Chadwick R, Calvert A, HARRAP K . Pharmacokinetics of cis-diammine-1,1-cyclobutane dicarboxylate platinum(II) in patients with normal and impaired renal function. Cancer Res. 1984; 44(4):1693-7. View

18.

Canetta R, Bragman K, Smaldone L, Rozencweig M . Carboplatin: current status and future prospects. Cancer Treat Rev. 1988; 15 Suppl B:17-32. DOI: 10.1016/0305-7372(88)90031-x. View

19.

Reyno L, Egorin M, Canetta R, Jodrell D, Swenerton K, Pater J . Impact of cyclophosphamide on relationships between carboplatin exposure and response or toxicity when used in the treatment of advanced ovarian cancer. J Clin Oncol. 1993; 11(6):1156-64. DOI: 10.1200/JCO.1993.11.6.1156. View

20.

Gormley P, Bull J, LeRoy A, Cysyk R . Kinetics of cis-dichlorodiammineplatinum. Clin Pharmacol Ther. 1979; 25(3):351-7. DOI: 10.1002/cpt1979253351. View